RNAimmune

company

About

RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$27M
Industries
Biotechnology,Health Care,Life Science
Founded date
Jan 1, 2020
Number Of Employee
1 - 10
Operating Status
Active

RNAimmune is a biopharmaceutical company specializing in the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. The company leverages mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. RNAimmune is a spin-off venture from Sirnaomics, Inc. has received a global exclusive right to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery from Sirnaomics. The company has also developed a proprietary A.I. algorithm (ALEPVA) for antigen prediction and vaccine design. By integrating multiple established platform technologies, the company is aiming to develop a comprehensive mRNA drug discovery and development platform, from which the company will enrich its therapeutic and vaccine product pipeline addressing tremendous unmet needs in treatments of viral infections, cancer, and rare diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$37M
RNAimmune has raised a total of $37M in funding over 2 rounds. Their latest funding was raised on Mar 29, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 29, 2022 Series A $27M 1 Sirnaomics Detail
Apr 21, 2021 Seed $10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
1
RNAimmune is funded by 1 investors. Sirnaomics are the most recent investors.
Investor Name Lead Investor Funding Round
Sirnaomics Yes Series A